Natera
NTRA
$267.76
-0.70%
Natera is a diagnostic and research company specializing in molecular and bioinformatics technology, offering products like the Panorama Non-Invasive Prenatal Test (NIPT), Horizon Carrier Screening, Signatera molecular residual disease (MRD) test, and Prospera for organ transplant rejection monitoring. It operates in the medical diagnostics and research industry, with a strong focus on oncology and reproductive health. The company is a market leader in non-invasive prenatal testing and is gaining traction in oncology with its Signatera MRD test, positioning itself as a high-growth disruptor in precision medicine. The current investor narrative centers on Natera's accelerating revenue growth, driven by expanding test volumes and commercial execution, while the path to profitability remains a key debate as the company narrows losses and generates positive free cash flow.…
NTRA
Natera
$267.76
Related headlines
Investment Opinion: Should I buy NTRA Today?
Rating: Buy. Natera's accelerating revenue growth, improving margins, and strong balance sheet make it a compelling growth investment, supported by a Strong Buy analyst consensus and 8.0% upside to the average target of $282.86.
Supporting Evidence: Revenue grew 38.8% YoY in Q1 2026, accelerating from 24.2% a year ago. Gross margin improved to 64.8% from 58.8% in Q2 2024, and operating margin improved to -13.4% from -20.2%. Free cash flow turned positive at $18.0 million in Q1 2026, with TTM FCF of $92.0 million. The trailing PS of 13.6x is near historical lows, and the forward PS of 5.6x implies significant growth is priced in but achievable.
Risks & Conditions: The biggest risks are growth deceleration and failure to reach profitability. This Buy rating would be downgraded to Hold if revenue growth falls below 25% or if operating losses widen. The stock is fairly valued relative to its growth rate, but a premium to the industry is justified by its 38.8% growth. Natera is not overvalued given its accelerating revenue and improving profitability, but it is not a deep value play.
Sign up to view all
NTRA 12-Month Price Forecast
Natera's accelerating revenue growth and improving profitability metrics support a bullish stance, but the high valuation and ongoing losses warrant medium confidence. The key factor is whether the company can sustain 35%+ growth while moving toward profitability. If growth remains strong and margins continue to improve, the stock could reach the high target. However, any signs of deceleration or competitive pressure could trigger a re-rating. The stance would be upgraded to high confidence if the company reports GAAP profitability, and downgraded to neutral if growth falls below 25%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $282.86 and implied upside of +5.6% versus the current price.
Average Target
$282.86
0 analysts
Implied Upside
+5.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$193 - $330
Analyst target range
Natera is covered by 21 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.5 on a 1-5 scale). The average target price is $282.86, implying an 8.0% upside from the current price of $261.99. The distribution leans heavily bullish, with no sell ratings and a strong buy consensus, reflecting confidence in the company's growth trajectory. The target range spans from a low of $193.00 to a high of $330.00. The high target of $330.00 assumes continued revenue acceleration and margin expansion, while the low target of $193.00 prices in potential competitive pressures or slower growth. Recent ratings from firms like Canaccord Genuity (Buy), Morgan Stanley (Overweight), and Evercore ISI (Outperform) indicate sustained bullish sentiment, though Goldman Sachs downgraded to Neutral from Buy in June 2026, signaling some caution. The wide spread between low and high targets ($137) reflects high uncertainty, but the consensus remains strongly positive.
Drowning in data?
Find the real signal!
Bulls vs Bears: NTRA Investment Factors
Natera presents a compelling growth story with accelerating revenue, improving margins, and a strong balance sheet, supported by a bullish analyst consensus. However, the stock trades at a high PS multiple and is not yet profitable, with a Goldman Sachs downgrade adding caution. The bull case is stronger given the accelerating growth trajectory and path to profitability, but the key tension is whether the company can sustain 30%+ revenue growth while achieving GAAP profitability. If growth decelerates or losses persist, the premium valuation could compress significantly.
Bullish
- Accelerating Revenue Growth: Revenue grew 38.8% YoY in Q1 2026 to $696.6 million, accelerating from 32.0% in Q4 2025 and 24.2% in Q1 2025, driven by strong demand for Signatera and other tests.
- Improving Profitability Trajectory: Operating margin improved to -13.4% in Q1 2026 from -20.2% in Q2 2025, and free cash flow turned positive at $18.0 million in Q1 2026, with TTM FCF of $92.0 million.
- Strong Balance Sheet: Current ratio of 3.39 and debt-to-equity of 0.125 indicate minimal leverage and ample liquidity to fund growth without dilutive financing.
- Bullish Analyst Consensus: 21 analysts rate the stock a Strong Buy (mean 1.5/5), with an average target of $282.86, implying 8.0% upside. High target of $330 suggests 25.9% upside.
Bearish
- High Valuation Multiple: Trailing PS ratio of 13.6x is elevated, though near historical lows. Forward PS of 5.6x still implies aggressive growth expectations that may not materialize.
- Not Yet Profitable: Net loss of $85.1 million in Q1 2026, though narrowing. ROE of -12.2% and negative net margins (-9.0%) indicate ongoing losses.
- Goldman Sachs Downgrade: Goldman Sachs downgraded to Neutral from Buy in June 2026, signaling caution on valuation or growth sustainability.
- High Beta and Volatility: Beta of 1.505 implies 50.5% more volatility than the market, amplifying downside risk in a downturn. Short ratio of 3.66 days indicates elevated short interest.
NTRA Technical Analysis
Natera is in a strong uptrend, with the stock up 85.7% over the past year, significantly outperforming the S&P 500's 16.5% gain. The current price of $261.99 sits at 81.9% of its 52-week range ($131.81 to $288.04), indicating the stock is near the upper end of its range, reflecting sustained bullish momentum but also potential overextension. This positioning suggests the market is pricing in continued growth optimism, though it leaves limited room for error. Short-term momentum is robust, with the stock gaining 28.6% over the past three months and 0.8% in the last month, showing acceleration from the longer-term trend. The 1-month change of 0.8% aligns with the 1-year trend, indicating no divergence, while the 3-month gain of 28.6% outpaces the S&P 500's 3.5% return, confirming strong relative strength. The stock's beta of 1.505 implies 50.5% more volatility than the market, which amplifies both upside and downside moves. Key support is at the 52-week low of $131.81, while resistance is at the 52-week high of $288.04. A breakout above $288.04 would signal a continuation of the uptrend, while a breakdown below $131.81 would indicate a bearish reversal. The elevated beta suggests investors should size positions accordingly to manage risk.
Beta
1.50
1.50x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$132-$288
Price range past year
Annual Return
+100.3%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | +0.2% |
| 3m | +29.2% | +3.7% |
| 6m | +15.8% | +8.0% |
| 1y | +100.3% | +18.2% |
| ytd | +17.0% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory is accelerating, with Q1 2026 revenue of $696.6 million, up 38.8% year-over-year, compared to 32.0% growth in Q4 2025 and 24.2% in Q1 2025. The oncology segment, including Signatera, is a key growth driver, while the product revenue of $693.9 million in Q1 2026 highlights strong commercial execution. This accelerating growth supports the investment case for a company scaling its test volumes and expanding market share. The company is not yet profitable, with a net loss of $85.1 million in Q1 2026, but the loss is narrowing from $100.9 million in Q2 2025. Gross margin improved to 64.8% in Q1 2026 from 58.8% in Q2 2024, indicating operating leverage. Operating margin was -13.4% in Q1 2026, improving from -20.2% in Q2 2025, reflecting cost discipline. The trajectory toward profitability is a positive signal, though the company remains in the red. Natera has a strong balance sheet with a current ratio of 3.39 and a low debt-to-equity ratio of 0.125, indicating minimal leverage. Free cash flow was positive at $18.0 million in Q1 2026, and trailing twelve-month free cash flow reached $92.0 million, showing the company can fund growth internally. ROE was -12.2%, reflecting the net loss, but the improving cash flow and low debt reduce financial risk.
Quarterly Revenue
$696644000.0B
2026-03
Revenue YoY Growth
+38.8%
YoY Comparison
Gross Margin
64.8%
Latest Quarter
Free Cash Flow
$92010000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Since Natera has negative net income (net loss of $85.1 million in Q1 2026), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 13.6x, while the forward PS ratio (based on estimated revenue of $5.59 billion) is approximately 5.6x, implying the market expects significant revenue growth. The gap between trailing and forward PS suggests aggressive growth expectations are priced in. Compared to the industry average PS ratio (data not provided), Natera's PS of 13.6x is likely at a premium given its high growth rate. The company's 38.8% revenue growth justifies a premium, but the valuation is stretched relative to slower-growing peers. Historically, Natera's PS ratio has ranged from 17.3x (Q2 2022) to 70.4x (Q2 2021), with the current 13.6x near the lower end of its historical range. This suggests the stock is relatively cheaper than its own history, potentially offering value if growth continues. However, the historical low PS of 13.6x still reflects a high-growth premium.
PE
-150.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Natera's net loss of $85.1 million in Q1 2026, though narrowing, means the company is still unprofitable with a negative net margin of -9.0%. The operating margin of -13.4% indicates ongoing operational losses, though improving from -20.2% in Q2 2025. The company's high reliance on revenue growth to justify its 13.6x PS ratio means any deceleration could lead to multiple compression. However, the low debt-to-equity of 0.125 and positive free cash flow of $92.0 million TTM provide a cushion against cash burn.
Market & Competitive Risks: The stock's beta of 1.505 makes it highly sensitive to market downturns, with a 1-year relative strength of 69.3% vs. the S&P 500, suggesting potential mean reversion. The diagnostics market is competitive, with rivals like Guardant Health and Exact Sciences in oncology. Regulatory risks include changes in reimbursement for NIPT or MRD tests. The Goldman Sachs downgrade to Neutral in June 2026 highlights valuation concerns, and the short ratio of 3.66 days indicates bearish sentiment.
Worst-Case Scenario: A combination of revenue growth deceleration below 20%, failure to achieve GAAP profitability, and a broad market sell-off could drive the stock to its 52-week low of $131.81, representing a 49.7% decline from the current price of $261.99. This scenario could be triggered by competitive pressures, regulatory setbacks, or a macro downturn compressing growth stock multiples.
FAQ
The key risks are: (1) Growth deceleration – if revenue growth falls below 25%, the premium PS multiple could compress significantly. (2) Profitability risk – the company is still unprofitable with a net loss of $85.1 million in Q1 2026, and any delay in achieving profitability could weigh on sentiment. (3) Competitive and regulatory risk – the diagnostics market is competitive, and changes in reimbursement for NIPT or MRD tests could pressure margins. (4) Macro risk – with a beta of 1.505, the stock is highly sensitive to market downturns. The most severe risk is a combination of growth deceleration and a broad market correction, which could drive the stock to its 52-week low of $131.81, a 49.7% decline.
The 12-month forecast is positive, with a base case probability of 50% for the stock to trade between $262 and $283, driven by continued revenue growth of 35-38% and margin improvement. The bull case (30% probability) sees the stock reaching $288-$330 if growth accelerates above 40% and profitability is achieved. The bear case (20% probability) sees the stock falling to $193-$132 if growth decelerates below 25% or losses persist. The most likely scenario is the base case, assuming the company maintains its growth trajectory and continues to narrow losses.
NTRA's trailing PS ratio of 13.6x is high in absolute terms but near the lower end of its historical range (17.3x to 70.4x), suggesting it is relatively cheaper than its own history. The forward PS of 5.6x implies the market expects significant revenue growth, which is supported by the 38.8% YoY growth rate. Compared to the industry average (not provided), the premium is justified by Natera's superior growth. The stock is fairly valued for a high-growth company, but it is not a value play. If growth sustains above 35%, the current valuation is reasonable; if growth decelerates, the stock could be overvalued.
NTRA is a good buy for growth investors willing to accept higher volatility. The stock has strong momentum with 85.7% gains over the past year and a consensus Strong Buy rating from 21 analysts, with an average target price of $282.86 implying 8.0% upside. However, the stock trades at a trailing PS of 13.6x, which is elevated but near historical lows, and the company is not yet profitable. The biggest downside risk is a growth deceleration or failure to achieve profitability, which could drive the stock to the low target of $193 or lower. For investors with a long-term horizon and tolerance for volatility, NTRA offers attractive risk/reward given its accelerating revenue growth and improving margins.
NTRA is more suitable for long-term investment given its growth stage and volatility. The company is still in a high-growth phase with accelerating revenue and improving margins, but it is not yet profitable. Short-term traders may benefit from momentum, but the stock's beta of 1.505 and short ratio of 3.66 days indicate high volatility and potential for sharp moves. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to achieve profitability and realize its full potential. The stock does not pay a dividend, so returns are entirely dependent on capital appreciation.